Patents by Inventor Wim Robberecht

Wim Robberecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Single domain antibodies against SOD1 and their use in medicine
    Patent number: 9862777
    Abstract: The present application relates to the field of single-domain antibodies (also called nanobodies), more particularly single-domain antibodies against SOD1 protein isoforms. It also relates to the use of these nanobodies in medicine. Accordingly, methods to treat a disease using these nanobodies are provided herein. The single-domain antibodies are particularly envisaged for treatment of ALS.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: January 9, 2018
    Assignees: VIB VZW, LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Wim Robberecht, Frederic Rousseau, Joost Schymkowitz
  • SINGLE DOMAIN ANTIBODIES AGAINST SOD1 AND THEIR USE IN MEDICINE
    Publication number: 20160115245
    Abstract: The present application relates to the field of single-domain antibodies (also called nanobodies), more particularly single-domain antibodies against SOD1 protein isoforms. It also relates to the use of these nanobodies in medicine. Accordingly, methods to treat a disease using these nanobodies are provided herein. The single-domain antibodies are particularly envisaged for treatment of ALS.
    Type: Application
    Filed: May 28, 2014
    Publication date: April 28, 2016
    Inventors: Wim Robberecht, Frederic Rousseau, Joost Schymkowitz
  • HDAC inhibitors to treat charcot-marie-tooth disease
    Patent number: 9238028
    Abstract: The disclosure relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, such as Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: January 19, 2016
    Assignees: VIB VZW, Life Sciences Research Partners VZW
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
    Publication number: 20160000766
    Abstract: The present application relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, most particularly, Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Application
    Filed: September 16, 2015
    Publication date: January 7, 2016
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • EphA4 is a disease modifier in motor neuron disease
    Patent number: 9187784
    Abstract: The present application relates to the field of motor neuron diseases, most particularly to amyotrophic lateral sclerosis and spinomuscular atrophy. Provided herein are strategies to improve symptoms and increase survival in patients with these axonopathies by inhibiting signaling mediated by the EphA4 ephrin receptor.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: November 17, 2015
    Assignees: VIB VZW, Life Sciences Research Partners VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventor: Wim Robberecht
  • HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
    Publication number: 20140329849
    Abstract: The disclosure relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, such as Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 6, 2014
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • EPHA4 IS A DISEASE MODIFIER IN MOTOR NEURON DISEASE
    Publication number: 20140143897
    Abstract: The present application relates to the field of motor neuron diseases, most particularly to amyotrophic lateral sclerosis and spinomuscular atrophy. Provided herein are strategies to improve symptoms and increase survival in patients with these axonopathies by inhibiting signaling mediated by the EphA4 ephrin receptor.
    Type: Application
    Filed: May 14, 2012
    Publication date: May 22, 2014
    Applicant: VIB VZW
    Inventor: Wim Robberecht
  • HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
    Publication number: 20130227717
    Abstract: The present application relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, most particularly, Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Application
    Filed: October 6, 2011
    Publication date: August 29, 2013
    Applicant: Life Sciences Research Partners VZW
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • USE OF N-AMINOIMIDAZOLE CYTOPROTECTIVE COMPOUNDS FOR TREATING CELL DEATH AND/OR GSK-3 MEDIATED DISEASES
    Publication number: 20120283303
    Abstract: The present invention relates to the use of N-aminoimidazole or N-aminoimidazole thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes.
    Type: Application
    Filed: April 30, 2012
    Publication date: November 8, 2012
    Applicant: K.U.LEUVEN RESEARCH AND DEVELOPMENT
    Inventors: Christophe Pannecouque, Wim Robberecht, Miguel Stevens
  • USE OF N-AMINOIMIDAZOLE CYTOPROTECTIVE COMPOUNDS FOR TREATING CELL DEATH AND/OR GSK-3 MEDIATED DISEASES
    Publication number: 20090149523
    Abstract: The present invention relates to the use of N-aminoimidazole or N-aminoimidazole-thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes.
    Type: Application
    Filed: May 10, 2007
    Publication date: June 11, 2009
    Applicant: K.U.Leuven Research and Development
    Inventors: Christophe Pannecouque, Wim Robberecht, Miguel Stevens